Approved for use through 07/31/2006, OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO					Complete if Known			
		•			Application Number	Not yet assigned /0/752,25		
IN	IEODM.	ATION	ו חופר	I OSLIDE	Filing Date	Herewith 0//06/04		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					First Named Inventor	Steven D. Schwartz		
					Art Unit	Not yet assigned 2/2/		
					Examiner Name	Not yet assigned Joseph P. High		
Sheet	1		of	3	Attorney Docket Number	96700/855		

				T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
H	1	<sup>US-</sup> 6,185,548 B1	02-06-2001	Schwartz et al.	
<del></del>		US-			
		US-			
		US-			
		US-			<del>-</del>
		US-	_		
·		US-			
	-	US-			
		US-			
· -		US-			
		US-			
		US-			,
		US-			
		US-			-
		US-	<del></del>		

-	0::	FORE	IGN PATENT DOCU			
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)		Applicant of Cited Document		
						L
Examiner				Date		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Considered

Signature

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons at		nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it contains a valid OMB control number.
Substitute for form 1449/PTO		Complete if Known
	Application Number	Not yet assigned /0/752, 257
NFORMATION DISCLOSURE	Filing Date	Herewith 01/06/05
STATEMENT BY APPLICANT	First Named Inventor	Steven D. Schwartz
(Use as many sheets as necessary)	Art Unit	Not yet assigned 2/2/
(ose as many should as necessary)	Examiner Name	Not vet assigned Jacou P. Hirl

**Attorney Docket Number** 

96700/855

3

of

Sheet

2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
H	2	BAGDASSARIAN et al., Molecular Electrostatic Potential Analysis for Enzymatic Substrates, Competitive Inhibitors, and Transition-State Inhibitors. J. Am. Chem. Soc., 118:8825-36, 1996.	
#	3	BETTS et al., Cytidine Deaminase. The 2-3 Angstrom Crystal Structure of an Enzyme: Transition-state Analog Complex. J. Mol. Biol., 235:635-56, 1994:	
H	4	BOHM, New Approaches in Molecular Structure Prediction. Biophysical Chemistry, 59:1-32, 1996.	
H	5	BRUSIC et al., Prediction of MHC Class II-Binding Peptides Using an Evolutionary Algorithm and Artificial Neural Network. Bioinformatics, 14:121-30, 1998.	
4	6	EHRLICH and SCHRAMM, Electrostatic Potential Surface Analysis of the Transition State for AMP Nucleosidase and for Formycin 5'-Phosphate, a Transition-State Inhibitor. Biochem., 33:8890-96, 1994.	
H	7 ·	FRICK et al., Binding of Pyrimidin-2-one Ribonucleoside by Cytidine Deaminase as the Transition-State Analogue 3,4-Dihydrouridine and the Contribution of the 4-Hydroxyl Group to Its Binding Affinity, Biochemistry, 28:9423-30, 1989.	
#	8	GASTEIGER et al., Representation of Molecular Electrostatic Potentials by Topological Feature Maps. J. Am. Chem. Soc., 116:4608-20, 1994.	
H	9	HORENSTEIN and SCHRAMM, Electronic Nature of the Transition State for Nucleoside Hydrolase. A Blueprint for Inhibitor Design. Biochemistry, 32:7089-97, 1993.	
H	10	KLINE and SCHRAMM, Electrostatic Potential Surfaces of the Transition State for AMP Deaminase and for (R)-Coformycin, a Transition State Inhibitor. J. Biol Chem., 269:22385-90, 1994.	
H	11	SO and RICHARDS, Application of Neural Networks: Quantitative Structure-Activity Relationships of the Derivatives of 2,4-Diamino-5-(substituted-benzyl) pyrimidines as DHFR Inhibitors. J. Med. Chem., 35:3201-7, 1992.	

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this/form/with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. (Pointfidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Applicati n Number Not yet assigned INFORMATION DISCLOSURE **Filing Dat** Herewith-STATEMENT BY APPLICANT **First Named Inventor** Steven D. Schwartz Art Unit Not yet assigned-2 i Z (Use as many sheets as necessary) **Examiner Name** Not yet assigned **Attorney Docket Number** Sheet 3 3 96700/855

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
#	12	WAGENER et al., Autocorrelation of Molecular Surface Properties for Modeling Corticosteriod Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks. J. Am. Chem. Soc., 117:7769-75, 1995.	
H	13	WEINSTEIN et al., Predictive Statistics and Artificial Intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS. Stem Cells, 12:13-22, 1994.	
1			
		·	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.